Impact of Intermediate Hyperglycemia and Diabetes on Immune Dysfunction in Tuberculosis

Clare Eckold,1 Vinod Kumar,2,3 January Weiner,1 Bachti Alisjahbana,6,6, Anca-Leila Riza3,4,5, Katharina Ronacher4,5, Jorge Coronel1, Sarah Kerry-Barnard1,2, Stephanus T. Mulherbo5,6,7,8, Kim Stanley4,9, Revina Ruslami3,9, Mihai Ioana7,8, Cesar Ugarte-Gil1,13, Gerhard Walzl10, Reinout van Crevel9, Cisca Wijmenga2, Julia A. Critchley1,12, Hazel M. Dockrell1,a, and Jacqueline M. Cliff1,a; for the TANDEM consortiumb

1Tuberculosis Centre and Department of Infection and Biology, London School of Hygiene and Tropical Medicine, London, United Kingdom, 2University of Groningen, Department of Genetics, University Medical Center Groningen, Groningen, The Netherlands, 3Department of Internal Medicine and Radboud Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, The Netherlands, 4Max Planck Institute for Infection Biology, Berlin, Germany, 5TB-HIV Research Center, Faculty of Medicine, Universitas Padjadjaran, Bandung, Indonesia, 6Hasan Sadikin General Hospital, Bandung, Indonesia, 7Human Genomics Laboratory, University of Medicine and Pharmacy, Craiova, Romania, 8Regional Centre for Human Genetics–Dolj, Emergency Clinical County Hospital, Craiova, Romania, 9Mater Research Institute–University of Queensland, Translational Research Institute, Brisbane, Australia, 10South Africa Medical Research Council Centre for Tuberculosis Research, Department of Science and Technology/National Research Foundation Centre of Excellence for Biomedical Tuberculosis Research, Division of Molecular Biology and Human Genetics, Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa, 11Laboratorio de Investigación de Enfermedades Infecciosas, Universidad Peruana Cayetano Heredia, Lima, Peru, 12Population Health Research Institute, St George's, University of London, London, United Kingdom, and 13School of Medicine, Universidad Peruana Cayetano Heredia, Lima, Peru

(See the Editorial Commentary by Wilkinson on pages 79–81.)

Background. People with diabetes have an increased risk of developing active tuberculosis (TB) and are more likely to have poor TB-treatment outcomes, which may impact on control of TB as the prevalence of diabetes is increasing worldwide. Blood transcriptomes are altered in patients with active TB relative to healthy individuals. The effects of diabetes and intermediate hyperglycemia (IH) on this transcriptomic signature were investigated to enhance understanding of immunological susceptibility in diabetes-TB comorbidity.

Methods. Whole blood samples were collected from active TB patients with diabetes (glycated hemoglobin [HbA1c] ≥6.5%) or IH (HbA1c = 5.7% to <6.5%), TB-only patients, and healthy controls in 4 countries: South Africa, Romania, Indonesia, and Peru. Differential blood gene expression was determined by RNA-seq (n = 249).

Results. Diabetes increased the magnitude of gene expression change in the host transcriptome in TB, notably showing an increase in genes associated with innate inflammatory and decrease in adaptive immune responses. Strikingly, patients with IH and TB exhibited blood transcriptomes much more similar to patients with diabetes-TB than to patients with only TB. Both diabetes-TB and IH-TB patients had a decreased type I interferon response relative to TB-only patients.

Conclusions. Comorbidity in individuals with both TB and diabetes is associated with altered transcriptomes, with an expected enhanced inflammation in the presence of both conditions, but also reduced type I interferon responses in comorbid patients, suggesting an unexpected uncoupling of the TB transcriptome phenotype. These immunological dysfunctions are also present in individuals with IH, showing that altered immunity to TB may also be present in this group. The TB disease outcomes in individuals with IH diagnosed with TB should be investigated further.

Keywords. tuberculosis; diabetes; inflammation; hyperglycemia.

Despite much research, precise mechanisms underlying how the host immune response controls Mycobacterium tuberculosis are still not fully understood. Studies of comorbidity and coinfection associated with susceptibility to tuberculosis (TB) may provide useful insights. The epidemiological link between diabetes and TB has been known for centuries, yet the biological mechanisms underlying the association are still unclear [1]. People living with diabetes are 3 times more likely to develop active TB once infected [2], and are also more likely to have poor TB-treatment outcomes [3]. Ninety percent of diabetes cases worldwide are type 2 diabetes mellitus (T2DM) [4], characterized by insulin resistance and subsequent insulin insufficiency. Diabetes prevalence has risen from 108 million in 1980 to 415 million in 2014, with an estimated 642 million cases projected by 2040 [4]. The countries with the greatest number of people with diabetes include several countries with concurrent high TB burden, such as China, India, Brazil, Indonesia, and Bangladesh. The estimated population attributable fraction of diabetes for adult TB is estimated at 9%–17% across World Health Organization regions [5], surpassing that for human...
immunodeficiency virus (HIV) in most regions, emphasizing the critical need to target this population for TB control.

T2DM is characterized by a decrease in the ability of insulin to alter metabolism in target cells, leading to overproduction of insulin, pancreatic β-cell exhaustion, and eventual depletion of insulin, causing impaired glucose tolerance. Excessive glucose has toxic effects systemically, on major organs as well as on cells in the immune system. Additionally, T2DM is linked with obesity, with an increased number of adipocytes and with increased secretion of free fatty acids and of proinflammatory cytokines, including tumor necrosis factor-α, interleukin (IL) 1β, and IL-6 [6, 7], from adipocytes. In turn, these abnormalities in glucose control, dyslipidemia, and the chronic inflammatory response lead to an immune dysfunction disorder, affecting the body’s defence to M. tuberculosis. People with T2DM have impaired immune cell function, with reduced phagocytic ability in response to M. tuberculosis, which is correlated with poor glycemic control [8]. Alongside chronic inflammation, including elevated circulating proinflammatory cytokines, people with T2DM-TB comorbidity have enhanced type 1 [9, 10] and regulatory T-cell responses [11] to M. tuberculosis antigens (reviewed in [12]).

Spectrums exist in both TB and T2DM, from latent M. tuberculosis infection through subclinical incipient TB to active TB disease [13], and from nondiabetes to clinically manifest diabetes via intermediate hyperglycemia (IH). Although not completely sensitive, glycated hemoglobin (HbA1c) measurement can determine an individual’s point along this spectrum, with the current threshold for diabetes diagnosis at HbA1c ≥6.5%, and for intermediate hyperglycemia at HbA1c = 5.7% to <6.5% [14]. IH has become an area of interest because it has also been shown to be associated with TB [15, 16].

Blood transcriptomic changes in TB patients have been well described: Active TB patients are distinct from healthy controls (HCs), exhibiting a neutrophil-derived interferon (IFN) signature. This resolves controls (HCs), exhibiting a neutrophil-derived interferon (IFN) and inflammatory response [18] signature. This resolves during successful TB drug treatment [19, 20], and the blood transcriptome in TB is distinct from that in other diseases [21, 22]. Blood-based transcriptomic studies of people living with diabetes are scarce. A recent study [23] found few differences in transcriptomes between TB-only patients and those with T2DM and TB comorbidity, although TB patients with IH were not defined in this study.

Here, we used an unbiased RNA-seq approach to identify immunological pathways that were altered in T2DM-TB comorbidity compared to TB only, and we also investigated the impact of IH on TB, in order to understand why diabetes increases susceptibility to TB, and whether individuals with IH might also be at increased risk.

METHODS

Patient Recruitment

Adults with newly diagnosed, bacteriologically confirmed pulmonary TB with and without diabetes were recruited between December 2013 and February 2016 at 4 different study sites: Cape Town, South Africa (SUN); Bandung, Indonesia (UNPAD); Lima, Peru (UPCH); and Craiova, Romania (UMFCV). In South Africa and Romania, people with diabetes mellitus (DM) but without TB and healthy individuals were also recruited. Patients were excluded if they were already taking TB treatment, had multidrug-resistant TB, were HIV positive, were pregnant, were taking corticosteroids, or had other serious comorbidity. DM was classified as a laboratory test of HbA1c ≥6.5%, alongside a confirmatory HbA1c ≥6.5% or fasting blood glucose ≥7 mmol/L, as described in this cohort [24]. Patients with IH were characterized with an HbA1c reading of 5.7% to <6.5%. Patients without diabetes, including HCs, had HbA1c values of <5.7%. All patients gave written informed consent, and the study was approved by the London School of Hygiene and Tropical Medicine Observational/Interventions Research Ethics Committee (6449, 11 July 2013) as well as the SUN Health Research Ethics Committee (N13/05/064, 29 July 2013), the UNPAD Health Research Ethics Committee, Faculty of Medicine, Universitas Padjadjaran (number 377/UN6.C2.1.2/KEPK/PN/2012), the UMFCV Committee of Ethics and Academic and Scientific Deontology (94, 6 September 2013), and the UPCH Institutional Committee of Ethics in Investigation (61069, 2 September 2013).

To limit confounding, prior to conducting the RNA-seq analysis, patient characteristic variables (age, body mass index [BMI], HbA1c) for each clinical group and for each study setting were initially tested using analysis of variance. Subsequently, variables were tested for normality using the Shapiro-Wilk test: If deemed normally distributed, a pairwise t test was performed, if not, a nonparametric Wilcoxon rank-sum test was performed. The participant ethnicities were recorded.

RNA-seq Experiments

Venous blood was collected at TB diagnosis, before initiation of TB treatment, into PAXgene Blood RNA Tubes (PreAnalytiX) and used for RNA-seq analysis, using the polyA tail library preparation method and single-read sequencing (n = 249). Sequencing FASTQ files were aligned to the human genome, and transcript quantification, differential gene expression, biological characterization, and machine learning were performed as described in the Supplementary Methods. RNA-seq quality control data are shown in Supplementary Figure 1 and Supplementary Table 1.

RESULTS

Study Population

A total of 151 TB patients were recruited from 4 locations in South Africa, Romania, Indonesia, and Peru, and classified as having TB only, IH-TB, or DM-TB, depending on laboratory HbA1c results at the time of TB diagnosis (Table 1). The DM-TB group included some patients with
previously diagnosed DM, some of whom were taking insulin (Supplementary Table 2). Additionally, in South Africa and Romania, individuals without disease (HCs) and DM only were recruited. The ages of the participants were not significantly different across the disease categories in any site or when the sites were combined (median age: 46 years for TB only; 46 years for IH-TB; and 49 years for DM-TB; Table 1). As anticipated, the BMI was significantly greater in the DM patients than in all the other patient groups at all sites (Table 1). Overall, participants had 10 different stated ethnic backgrounds, but the participants’ ethnicities were not different across disease groups within each site.

**Blood TB Transcriptome Signature**

First, the effect of DM and IH on gene expression changes in TB patients’ blood was investigated in South African samples. As expected, there was substantial up-regulation of gene expression (345 genes) in TB patients compared to HCs (Figure 1A), including up-regulated expression of genes such as complement component C1QA, B, C, and C2; BATF2; SOCS3; Septin 4; ANKRD22; and GBP5, which have been observed previously [20, 25, 26] (Figure 1A). Diabetes alone had a very different impact on the blood transcriptome, with larger numbers of genes differentially expressed, but with low magnitude of change and lower statistical significance (Figure 1B). In contrast, DM had a substantial impact on the blood transcriptome in TB patients, with 1695 genes significantly up-regulated in DM-TB patients compared to HCs, including many ribosomal and transmembrane proteins, as well as proinflammatory cytokines such as IL-1β, IL-15, and IL-18 and the regulatory cytokine IL-10. There were also 1623 genes significantly down-regulated in the DM-TB group compared to HCs, including several zinc finger transcription factors and cytokines such as IL-8, IL-16, and IL-24. Notably, patients with IH-TB exhibited an even greater perturbation of their blood transcriptome relative to HCs, with 2576 genes significantly up-regulated and 2140 genes significantly down-regulated (Figure 1D). These results show that diabetes impacts the peripheral host response to TB and that this effect is already present in individuals with IH. Supplementary Table 3 details all of the differentially expressed genes in the South African cohort. Supplementary Figure 2 shows that sex had no impact on gene expression differences.

These data were validated in a separate patient cohort, recruited in Romania. Similarly large-scale up- and down-regulation of gene expression in both DM-TB and IH-TB were observed relative to HCs, to a much greater extent than that seen in TB only (Supplementary Figure 3). Direct comparison of differentially expressed gene lists in South Africa and Romania showed significant overlap in each case (GeneOverlap P < .05; Supplementary Figure 4).

**Table 1. Characteristics of Study Participants**

| Characteristic | Country          | TB Only | IH-TB | DM-TB | T2DM Only | Healthy Controls | P Value (ANOVA) |
|----------------|------------------|---------|-------|-------|-----------|------------------|-----------------|
| No. of study participants | South Africa     | 11      | 20    | 15    | 33        | 24               |                 |
|                 | Romania          | 10      | 10    | 15    | 19        | 12               |                 |
|                 | Indonesia        | 14      | 5     | 19    |           |                  |                 |
|                 | Peru             | 11      | 9     | 12    |           |                  |                 |
|                 | All sites        | 46      | 44    | 61    |           |                  |                 |
| Age, y, median (range) | South Africa     | 48 (31–56) | 44.5 (25–57) | 46 (27–57) | 49 (29–64) | 42 (30–70) | .168            |
|                 | Romania          | 43 (30–64) | 48.5 (22–63) | 47 (22–64) | 55 (38–65) | 46 (38–61) | .329            |
|                 | Indonesia        | 47 (28–62) | 51 (37–54) | 52 (33–66) |           |                  | .430            |
|                 | Peru             | 55 (31–69) | 52 (31–68) | 50.5 (42–58) |           |                  | .928            |
|                 | All sites        | 46 (28–69) | 46 (22–68) | 49 (22–66) |           |                  | 2645            |
| Sex, % (No. male/female) | South Africa     | 18 (2/9) | 60 (12/8) | 47 (7/8) | 45 (15/18) | 50 (12/12) |                 |
|                 | Romania          | 60 (6/4) | 90 (9/1) | 87 (13/2) | 73 (14/5) | 83 (10/2) |                 |
|                 | Indonesia        | 50 (7/7) | 80 (4/1) | 58 (11/8) |           |                  |                 |
|                 | Peru             | 45 (5/6) | 55 (5/4) | 50 (6/6) |           |                  |                 |
|                 | All sites        | 43 (26/20) | 68 (30/14) | 60 (37/24) |           |                  |                 |
| BMI, kg/m², median (range) | South Africa     | 20.1 (14.8–24.1) | 18.4 (13.7–27.1) | 19.1 (13.9–32.3) | 29 (20.52–52.54) | 23.7 (17.87–45.20) | 1.43x10[-8] |
|                 | Romania          | 20.65 (17.7–25.5) | 21 (15.5–22) | 21.5 (15.3–36.1) | 28.7 (13.1–37.8) |           | 6.73x10[-4] |
|                 | Indonesia        | 19.8 (13.76–33.27) | 18.67 (13.9–20.09) | 19.52 (16.10–31.73) |           |                  | .242            |
|                 | Peru             | 23.98 (17.35–28.96) | 21.94 (18.67–25.56) | 22.7 (20.55–33.33) |           |                  | .207            |
|                 | All sites        | 20.94 (13.76–33.27) | 19.44 (13.7–27.1) | 21.5 (13.9–36.1) |           |                  | 1.67x10[-3] |
| HbA1c, %, median (range) | South Africa     | 5.3 (4.8–5.7) | 6 (5.7–6.3) | 10.8 (6.5–14.3) | 10.1 (4.7–14.9) | 5.3 (4.8–5.6) | 2.2x10[-16] |
|                 | Romania          | 5.5 (5.2–5.7) | 6 (5.7–6.4) | 10.4 (6.6–15) | 9 (7–14) | 5.4 (5.2–5.6) | 1.2x10[-13] |
|                 | Indonesia        | 5.55 (5.5–6.7) | 5.9 (5.8–6) | 11.9 (75–15.9) |           |                  | 3.2x10[-12] |
|                 | Peru             | 5.5 (5.1–5.7) | 5.8 (5.7–6.1) | 11.4 (7.1–15.2) |           |                  | 8.33x10[-9] |
|                 | All sites        | 5.5 (4.8–5.7) | 5.95 (5.7–6.4) | 11 (6.5–15.9) |           |                  | 2.2x10[-16] |

Abbreviations: ANOVA, analysis of variance; BMI, body mass index; DM-TB, diabetes mellitus–tuberculosis; HbA1c, glycated hemoglobin; IH-TB, intermediate hyperglycemia–tuberculosis; T2DM, type 2 diabetes mellitus; TB, tuberculosis.
Log fold change (FC)–FC plots demonstrate concordant and discordant differential expression of genes when samples in different disease categories are compared to controls; discordant genes show significant differences in both comparisons, yet in opposite directions, whereas concordant genes show significant differences in both comparisons in the same direction. Here, all 4 disease groups with HCs in the South African cohort were compared (Figure 2). The main differences, showing the most discordance, were seen between the DM-only group vs HC comparison against all 3 comparisons of patients with TB (TB only vs HCs; DM-TB vs HCs; and IH-TB vs HCs), showing that the TB transcriptome is dominant. The greatest concordance was between DM-TB vs HCs and IH-TB vs HCs, showing that patients in these categories exhibited similar changes in blood gene expression. The comparison between TB only vs HCs and IH-TB vs HCs showed quantitative differences, with concordance between the genes but to a larger degree in the IH-TB group, indicating extra perturbation when hyperglycemia is present (Figure 2).

To determine whether differential gene expression could be used to discriminate disease phenotype, principal component analysis (PCA) was performed on all study participants from South Africa. The resulting PCA plot, based on the differentially expressed genes from the initial analysis, showed 2 main clusters: HCs and people with DM only clustered together, while the second main cluster comprised people with IH-TB and DM-TB comorbidity (Figure 3).

Modular Analysis in DM and TB Comorbidity
Modular analysis, which tests for enrichment sets of co-regulated genes sharing related biological functions [27, 28], was performed. As observed previously [17, 20], in the South African cohort, TB-only patients exhibited up-regulation of specific modules, including the type I IFN.
Blood Transcriptomes in Patients With TB and Diabetes • CID 2021:72 (1 January) • 73

response, complement, and activated dendritic cells (Figure 4 and Supplementary Figure 5). In contrast, in diabetes patients, mainly respiration and protein synthesis modules were significantly up-regulated compared to HCs; these changes were not present in the comorbidity groups. Notably, module enrichments in DM-TB and IH-TB patients were similar to each other, which included up-regulation of modules differentially expressed in the TB-only group with a greater magnitude, especially for modules related to the inflammatory response and to myeloid cell function. There was stronger down-regulation of modules in IH-TB and DM-TB groups compared to TB only: these included natural killer (NK) cell modules and adaptive immune response modules such as T-cell activation, differentiation, and B cells (Figure 4).
Figure 4. Transcriptional modules that were significantly differentially expressed in tuberculosis (TB)-only, diabetes mellitus (DM)-TB, intermediate hyperglycemia (IH)-TB, and DM only compared to healthy controls in South Africa before initiation of TB treatment. Transcripts were evaluated using a preexisting modular framework. Significantly up-regulated (red) and down-regulated (blue) modules are shown: the length of each bar corresponds to the effect size (magnitude of change) of that module, and the color saturation represents the adjusted P-value (<.0001). The amount of color represents the proportion of genes within that module that were differentially expressed.
Interferon and Inflammatory Responses
To determine the reproducibility of results across geographical regions and different patient ethnicities, RNA-seq data from DM-TB, IH-TB, and TB-only patients from all 4 study sites were combined. There was no systematic bias due to sample origin site (Supplementary Figure 6). In the combined dataset, DM-TB and IH-TB patients showed similar altered gene expression patterns in blood compared to patients with TB only (Figure 5). DM-TB patients had 292 up-regulated and 130 down-regulated genes, whereas IH-TB patients had 432 up-regulated and 126 down-regulated genes (Supplementary Table 4).

In modular analysis, both DM-TB and IH-TB showed a general trend of up-regulation, especially of modules involved in inflammation. Interestingly, however, patients with DM-TB and IH-TB also exhibited down-regulation of several IFN modules compared to TB only (Supplementary Figure 7). The most significantly differentially expressed are shown in Figure 6. The genes within these modules were differentially expressed in DM-TB and IH-TB, but of a greater magnitude in DM-TB, indicating an association with the extent of hyperglycemia.

Transcriptomic Signatures
We applied known Kaforou et al [29] and Sweeney et al [30] TB biomarker signatures that could distinguish TB from latent TB infection, to test validity in DM patients, using the random forest algorithm. As expected, the Kaforou signature validated well in our TB-only dataset (area under the curve [AUC] = 0.96; Figure 7, blue line). However, in the DM-TB comorbidity cohort, the performance was significantly reduced for both Kaforou (AUC = 0.87; Figure 7, orange line, test for difference between receiver operating characteristic [ROC] curves, \( P = .018 \)) and Sweeney (AUC = 0.84; Figure 7, green line) signatures. This implies that a TB biomarker signature for use in the general population needs to be derived from patient cohorts including those with DM. ROC curves showing sensitivities and specificities for these comparisons are shown in Supplementary Table 5.

DISCUSSION
The principal finding of this study was that DM comorbidity influences blood transcriptomes in patients with TB, weakening the performance of published TB biosignatures. Of potentially greater public health importance, the modulation seen with diagnosed DM was also evident in those with intermediate hyperglycemia, below the current HbA1c cutoff for DM diagnosis. There was greater up-regulation of genes involved in the inflammatory response in diabetes and TB comorbidity and also a reduced up-regulation of the IFN response, principally of genes in the type I IFN pathway.

Figure 5. Differential gene expression analysis of diabetes mellitus (DM)–tuberculosis (TB) and intermediate hyperglycemia (IH)–TB patients relative to TB-only patients, in the combined dataset from all 4 field sites. Samples collected in South Africa, Romania, Peru, and Indonesia from DM-TB (A) patients and IH-TB patients (B) were compared with patients with TB only in a combined analysis. Genes significantly differentially expressed after multiple testing correction are shown in black (\( P < .05 \)). Genes in gray are not statistically significantly altered compared to patients with untreated TB only. Abbreviation: FDR, false discovery rate.
IH-TB patients were more similar to DM-TB patients than to people with TB only, even though their hyperglycemia was below the diabetes diagnostic threshold. Separation of the TB patients with HbA1c <6.5% facilitated the discovery of differences between the groups, which was not clearly evident in a previous transcriptomics study [23]. Our results demonstrate that patients with intermediate levels of hyperglycemia exhibit immune dysfunction, which could lead to increased susceptibility to active TB disease. It was previously proposed that adverse effects and disease susceptibility would occur at higher HbA1c values, later in diabetes progression [31]. Infectious diseases, including TB, can themselves induce transient hyperglycemia [32] and poor outcome; further studies are warranted to establish the interplay between glycemic control, TB, and immune dysfunction. Targeted control of diabetes in TB could lead to better TB outcomes, and analysis of the direct impact of glycemic control in immune dysfunction is merited.

Developing TB control strategies targeting people with diabetes is critical, due to the rapidly increasing global T2DM burden, especially in countries with high TB incidence [33]. People living with diabetes have an increased risk of developing active TB following infection [34], and therefore this patient group may contribute disproportionately to onward TB transmission. DM-TB comorbidity is more likely to result in poor TB treatment outcomes [3], including failure and relapse, adding an extra burden on healthcare systems. Globally, population level diabetes interventions might provide effective TB control strategies [35].

In a parallel study conducted within the TANDEM Consortium analysis involving patients from the same 4 countries, TB patients with IH as well as with DM were more likely to be sputum smear positive compared to normoglycemic TB controls [24]. The impact of IH on TB disease susceptibility has been less well investigated, but in 2 studies conducted in India [15, 36] and 1 in Kenya [37], both IH and diabetes prevalences...
This study shows that TB patients with either IH or diabetes have an altered immune phenotype, characterized by an excessive inflammatory response and a reduced type I IFN response. Both TB [18] and DM are proinflammatory conditions, and a degree of synergy between the 2 diseases is likely responsible for driving lung pathology and clinical symptoms. In active TB only, type I IFN response genes are up-regulated compared to healthy infected and uninfected individuals [17, 20, 22, 38]. Although surmised to be a deleterious inflammatory response and a reduced type I IFN response, permitting continued growth of mycobacteria. Several IFN-related modules were present in the analysis performed, containing overlapping gene sets including genes encoding proteins involved in both type I and type II IFN pathways, all of which were all contained within the type I IFN response. Response is also affected, although we noted greater down-regulation of T-cell and NK-cell modules in IH-TB and DM-TB compared to TB alone. A recent study performed in Pakistan found raised serum concentrations of IFN-γ and IL-13 in both IH-TB and DM-TB, although TB patients with up to 1 month of anti-TB therapy were included [40]. Further work could also include an analysis of regulatory microRNAs and long noncoding RNAs, to understand better the mechanisms underpinning altered transcriptomes and immune responses in DM-TB.

Immunoological differences in DM-TB compared to TB only include enhanced proinflammatory responses [12], and increased circulating cytokines have also been described in IH-TB [41]. Immune abnormalities are detectable in individuals latently infected with M. tuberculosis with IH [42], and it is possible that concurrent intermediate hyperglycemia and latent TB infection drives the development of both diseases, in a similar manner to the synergism between TB and HIV disease. This may indicate a relationship between moderate HbA1c values and TB susceptibility that warrants careful clinical considerations, and investigation of clinical disease outcome.

To conclude, these data have uncovered an enhanced inflammatory profile together with decreased IFN responses, associated with DM-TB comorbidity, which may be responsible for the increased susceptibility to TB in people with diabetes. Furthermore, immune dysfunction exists even at intermediate levels of hyperglycemia, potentially causing TB susceptibility with implications for TB control. HbA1c values need to be considered in TB studies, as abnormal glycemia clearly affects the immune response.

**Supplementary Data**

Supplementary materials are available at *Clinical Infectious Diseases* online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.

**Notes**

*Acknowledgments.* The authors thank the clinical staff and the patients at the 4 study sites, as well as Bahram Sanjabi, Desiree Brandenburg-Weening, and Pieter van der Vlies for assistance with the RNA-seq.

*Members of the TANDEM (Concurrent Tuberculosis and Diabetes Mellitus; unraveling the causal link, and improving care) Consortium.* The TANDEM partners and collaborators include: H. Dockrell, J. Cliff, C. Eckold, D. Moore, U. Griffiths, and Y. Laurence (London School of Hygiene and Tropical Medicine, London, United Kingdom); R. Aarnouste, M. Netea; R. van Crevel, C. Ruesen, and E. Lachmandas (Radboud University Medical Center, Nijmegen, The Netherlands); S. Kaufmann, M. Beiger, and R. Golinski (Max Planck Institute for Infection Biology, Berlin, Germany); S. Joosten, T. Ottenhoff, F. Vridding, and M. Halvorsen (Leiden University Medical Center, Leiden, The Netherlands); G. Walzl, K. Ronacher, S. Malherbe, L. Kleyhans, B. Smith, K. Stanley, G. van der Spuy, A. Loxton, N. Chegou, M. Bosman, L. Thiart, C. Wagman, H. Thibhuvana, M. Selamolela, N. Prins, W. du Plessis, L. van Rensburg, and L. du Toit (Stellenbosch University, Cape Town, South Africa); J. Critchley, S. Kerry-Barnard, F. Pearson, and D. Grint (St Georges University of London, London, United Kingdom); S. McAllister, P. Hill, and A. Verrall (University of Otago, Dunedin, New Zealand); M. Ioana, A. Riza, R. Cioboata, M. Dudau, F. Nitu, I. Bazavan, M. Mota, S. G. Popa, A. Firanescu, A. Popa, I. Gheonea, S. Bicatu, A. Lepadat, I. Vladu, D. Clenciu, M. Bicu, C. Streba, A. Demetrian, M. Ciurea, A. Ciopeanu, C. Ciocoiu, S. Dorobantu, R. Plesea, E. L...
Potential Conflicts of Interest. All authors have submitted the ICMJE Form for Disclosure of Agreements.

Financial support. The research leading to these results, as part of the TANDEM Consortium, has received funding from the European Union’s Seventh Framework Programme (FP7 2007-2013 - Health) under grant agreement No 305279.

Potential conflicts of interest. The authors: No reported conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest.

References
1. Ronacher K, van Crevel R, Critchley JA, et al. Defining a research agenda to address the converging epidemics of tuberculosis and diabetes: part 2: underlying biologic mechanisms. Chest 2017; 152:174–80.
2. Al-Rifai RH, Pearson E, Critchley JA, Abu-Raddad Lj. Association between diabetes mellitus and active tuberculosis: a systematic review and meta-analysis. PLoS One 2017; 12:e0187567.
3. Baker MA, Harries AD, Joffe CY et al. The impact of diabetes on tuberculosis treatment outcomes: a systematic review. BMC Med 2011; 9:81.
4. International Diabetes Federation. IDF diabetes atlas. Brussels, Belgium: IDF 2017.
5. Lönroth K, Roglic G, Harries AD. Improving tuberculosis prevention and care through addressing the global diabetes epidemic: from evidence to policy and practice. Lancet Diabetes Endocrinol 2014; 2:730–9.
6. Spranger J, Kroke A, Möhlig M, et al. Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Diabetes 2003; 52:812–7.
7. Kado S, Nagase T, Nagata N. Circulating levels of interleukin-6, its soluble receptor and interleukin-6/receptor-6 complex proteins in patients with type 2 diabetes mellitus. Acta Diabetol 1999; 36:67–72.
8. Restrepo BI, Twahirwa M, Rahbar MH, Schlesinger LS. Phagocytosis via complement or Fc-gamma receptors is compromised in monocytes from type 2 diabetes patients with chronic hyperglycemia. PLoS One 2014; 9:e92977.
9. Kumar NP, Sridhar R, Banurekha VV, Jawahar MS, Nutman TB, Babu S. Expansion of pathogen-specific T-helper 1 and T-helper 17 cells in pulmonary tuberculosis with coincident type 2 diabetes mellitus. J Infect Dis 2013; 207:1476–82.
10. Stalenhoef JE, Alisjahbana B, Nelvan EJ, et al. The role of interferon-gamma in the increased tuberculosis risk in type 2 diabetes mellitus. Eur J Clin Microbiol Infect Dis 2008; 27:97–103.
11. Sun Q, Zhang Q, Xiao H, Cui H, Su B. Significance of the frequency of occurrence/2011/9789241502252_eng.pdf. Accessed 19 April 2020.
12. Ronacher K, Joosten SA, van Crevel R, Dockrell HM, Wald G, Ottenhoff TH. Acquired immunodeficiencies and tuberculosis: focus on HIV/AIDS and diabetes mellitus. Immunol Rev 2015; 264:121–37.
13. Suliman S, Thompson E, Sutherland J, et al. Four-genre pan-African blood signature predicts progression to tuberculosis. Am J Respir Crit Care Med 2018; 197:1198–208.
14. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2010; 33(Suppl 1):S82–9.
15. Viswanathan V, Kumpatla S, Aravindalochanan V, et al. Prevalence of diabetes and pre-diabetes and associated risk factors among tuberculosis patients in India. PLoS One 2012; 7:e41367.
16. Critchley JA, Restrepo BI, Ronacher K, et al. Defining a research agenda to address the converging epidemics of tuberculosis and diabetes; part 1: epidemiology and clinical management. Chest 2017; 152:165–73.
17. Berry MP, Graham CM, McNab FW, et al. An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis. Nature 2010; 466:973–7.
18. Joosten SA, Fletcher HA, Ottenhoff TH. A helicopter perspective on TB biomarkers: pathway and process based analysis of gene expression data provides new insight into TB pathogenesis. PLoS One 2013; 8:e73230.
19. Bloom CI, Graham CM, Berry MP, et al. Detectable changes in the blood transcriptome are present after two weeks of antituberculosis therapy. PLoS One 2012; 7:e46191.
20. Clift JM, Lee JS, Constantinou N, et al. Distinct phases of blood gene expression pattern through tuberculosis treatment reflect modulation of the humoral immune response. J Infect Dis 2013; 207:18–29.
21. Bloom CI, Graham CM, Berry MP, et al. Transcriptional blood signatures distinguish pulmonary tuberculosis, pulmonary sarcoidosis, pneumonias and lung cancers. PLoS One 2013; 8:e76030.
22. Maertzdorf J, Weiner J 3rd, Molleknopf HJ, et al; TBornTB Network. Common patterns and disease-related signatures in tuberculosis and sarcoidosis. Proc Natl Acad Sci U S A 2012; 109:7853–8.
23. Prada-Medina CA, Fukutani KE, Pavan Kumar N, et al. Systems immunology of diabetes-tuberculosis comorbidity reveals signatures of disease complications. Sci Rep 2017; 7:17999.
24. Ugarte-Gil C, Alisjahbana B, Ronacher K, et al. Diabetes mellitus among pulmonary tuberculosis-endemic countries: the TANDEM Study. Clin Infect Dis 2020; 70:780–8.